Key result
Trimetazidine significantly improved rest and peak systolic wall thickening score index (13% and 20.7%, P<0.001) and ejection fraction (19.7% and 14.1%, P<0.001) compared to placebo at 2 months.
Why the study?
Does trimetazidine improve left ventricular function and functional capacity in patients with ischaemic cardiomyopathy?
Population
38 patients with post-necrotic left ventricular dysfunction and multivessel coronary artery disease, mean…
Comparison
Trimetazidine 20 mg three times daily for 2… vs Placebo for 2 months, added to usual antianginal…
Design
RCT, randomized into two matched groups
Follow-up
2 months
Authors
Loading...
Supports trimetazidine in ischaemic cardiomyopathy; extends metabolic modulation evidence from this RCT.
RCT (n=38)
randomized
Does trimetazidine improve left ventricular function and functional capacity in patients with ischaemic cardiomyopathy?
p-value: p=<0.001
Trimetazidine improves myocardial contractile response, left ventricular function, and exercise capacity in patients with ischaemic cardiomyopathy.
Romualdo Belardinelli (2001) conducted an RCT in ischaemic cardiomyopathy (n=38). Trimetazidine vs. placebo was evaluated on rest and peak systolic wall thickening score index (p=<0.001). Trimetazidine significantly improved rest and peak systolic wall thickening score index (13% and 20.7%, P<0.001) and ejection fraction (19.7% and 14.1%, P<0.001) compared to placebo at 2 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: